.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Recent Developments in Management of Gynecologic Cancers

EP. 1: Systemic Therapy Selection for Advanced EOC

July 30th 2019

EP. 2: Targeted Therapy Options for Advanced Ovarian Cancer

July 30th 2019

EP. 3: Treatment Options for Patients with BRCA1/2

July 30th 2019

EP. 4: PARP Inhibitor Trial Updates

July 30th 2019

EP. 5: Managing Platinum-Resistance and Recurrent Disease

July 30th 2019

EP. 6: Maintenance Therapy: PARP Inhibitor or Bevacizumab

July 30th 2019

EP. 7: PARP Inhibitor Toxicity Management

July 30th 2019

EP. 8: PARP Inhibitor Mechanisms of Resistance

July 30th 2019

EP. 9: Cervical Cancer: Staging and Minimally Invasive Surgery

July 30th 2019

EP. 10: Frontline Therapies for Metastatic Cervical Cancer

July 30th 2019

EP. 11: Updates in Testing Endometrial Cancer Biomarkers

July 30th 2019

EP. 12: Standard Frontline Therapy for Endometrial Cancer

July 30th 2019

EP. 13: The Future of Managing Gynecologic Cancer

July 30th 2019